Showing results (171-180 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|August 24, 2019
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumoursBárbara Dos Santos Passaia, Keli Lima, Jean Lucas Kremer, et al.
Investigational New Drugs|August 30, 2019
The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinomaXi'an Li, Guangdong Hou, Zheng Zhu, et al.
Investigational New Drugs|March 13, 2021
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancersMing-Mo Hou, Ching-Liang Ho, Hsuan-Yu Lin, et al.
Investigational New Drugs|March 9, 2021
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumorsAnalia Azaro, Christophe Massard, William D Tap, et al.
Investigational New Drugs|October 21, 2022
Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancerToshiyuki Sumi, Motoki Sekikawa, Yuta Nagahisa, et al.
Investigational New Drugs|July 12, 2015
Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO)Jörg Thomas Hartmann, R D Issels, K San Nicolo, et al.
Investigational New Drugs|September 2, 2025
Advanced strategies to overcome multidrug resistance in cancer therapy: progress in P-glycoprotein inhibitors, drug delivery, and personalized medicineAnkitha Harish, N Deepika, Vedamurthy Joshi, et al.
Investigational New Drugs|September 3, 2025
Targeting the TRIB3-MYC axis in cancer: mechanistic insights and therapeutic disruption strategiesEmadeldin M Kamel, Sulaiman A Alsalamah, Ahmed A Allam, et al.
Investigational New Drugs|September 5, 2025
Targeting the Keap1/Nrf2 axis in cancer: molecular mechanisms and pharmacological interventionsYangchen Xia, Ziyang Xu, Xun Yuan, et al.
Investigational New Drugs|June 19, 2015
Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 doseKarthik Venkatakrishnan, Tae Min Kim, Chia-Chi Lin, et al.
Pageof 372